Therapy Trends KOL Insight: Bladder Cancer
KOLs expect Pfizer/Merck Group's Bavencio to be practice changing in the first-line maintenance treatment of locally advanced or metastatic urothelial cancer. But what impact will Bavencio have on the position of Merck & Co's Keytruda in the second-line setting? Will the new label extension for Keytruda in NMIBC and the prospect for combination therapy see it advance? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- Why are KOLs optimistic about the potential of Astellas/Seattle Genetics' antibody-drug conjugate, Padcev (enfortumab vedotin)?
- What insights do KOLs have for Janssen, Bayer and QED Therapeutics if use of FGFR therapies for locally advanced or metastatic UC who have susceptible gene mutations, is to expand?
- What are the expected benefits of novel intravesical therapies, such as FKD Therapies/Ferring's Adstiladrin (nadofaragene firadenovec) for patients with BCG-unresponsive NMIBC?
- Which combinations might signal the future for immunotherapy in urothelial carcinoma?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.